Desirudin
Also known as: CGP-39393, desirudin sodium, Desulfatohirudin, Hirudin variant-1, hirudin‑variant‑1, Iprivask, Revasc
Source Desirudin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Desirudin is a recombinant hirudin analog that directly inhibits thrombin. It is approved for prescription use as a subcutaneous anticoagulant, particularly when heparin is unsuitable, such as in heparin‑induced thrombocytopenia (HIT) or other thromboembolic conditions.
Mechanism of Action
Desirudin binds to the active site of thrombin, forming a stable complex that blocks thrombin's catalytic activity on fibrinogen, platelets, and other substrates. By preventing thrombin from converting fibrinogen to fibrin, it halts clot formation and reduces platelet activation, providing anticoagulation without relying on antithrombin or factor Xa pathways.
What the Research Shows
Review articles describe desirudin as one of several parenteral direct thrombin inhibitors approved in North America. Clinical contexts cited include prophylaxis and treatment of venous thromboembolism, management of HIT, acute coronary syndromes, and secondary prevention after coronary events. The literature highlights its recombinant nature, kinetic profile, and subcutaneous administration, but detailed trial data are not presented in the abstracts. Overall, desirudin is positioned as an alternative to heparin and vitamin K antagonists when those agents are limited by safety or practical concerns.
Reported Benefits
Evidence from the reviews indicates desirudin provides effective anticoagulation in settings where heparin is contraindicated, such as HIT, and can be used for VTE and ACS management. Its direct inhibition of thrombin offers a predictable anticoagulant effect without requiring antithrombin, and its subcutaneous route allows outpatient use.
Limitations of the Evidence
The abstracts do not provide head‑to‑head trial comparisons, so relative efficacy versus other direct thrombin inhibitors remains unclear. Desirudin is only available for injection, limiting convenience compared with oral agents. Long‑term safety data and specific dosing regimens are not detailed in the cited sources.
Safety Considerations
Bleeding is the principal adverse effect noted for direct thrombin inhibitors, including desirudin. Patients require monitoring for signs of hemorrhage, and dose adjustments may be needed in renal impairment, though the abstracts do not specify details. Injection site reactions can occur with subcutaneous delivery. Use is recommended when alternative anticoagulants are unsuitable.
How It Is Administered
Desirudin is administered by subcutaneous injection as a sterile peptide formulation. It is supplied for therapeutic use under prescription and is not indicated for oral administration.
Routes of Administration
Goals & Uses
- Acute coronary syndrome anticoagulationAnticoagulationLow
- Treatment of acute DVT/PETreatmentModerate
- Prevention of pulmonary embolismAnticoagulationModerate
- DVT prophylaxis after orthopedic surgeryPreventionHigh
- Heparin-induced thrombocytopenia (HIT) anticoagulationAnticoagulationModerate
- DVT prophylaxis after hip replacementAnticoagulation / ThromboprophylaxisHigh
Contraindications
- Known hypersensitivity to desirudin or any excipientAllergyHigh
- Spinal/epidural anesthesia with concurrent anticoagulant useAnestheticHigh
- Active major bleedingHemorrhagic RiskHigh
- Severe hepatic impairment (Child‑Pugh C)Liver DiseaseModerate
- Hypersensitivity to hirudins or desirudinImmunologicHigh
- Severe renal impairment (CrCl <31 mL/min)RenalHigh
- Irreversible coagulation disordersHematologicHigh
- Active bleeding or hemorrhagic diathesisHematologicHigh
Adverse Effects
- Hypersensitivity / allergic reactionsImmunologicRare
- Injection site reactionsLocalCommon
- ThrombocytopeniaHematologicRareLow platelet count
- Bleeding (major and minor)HematologicalCommon
- AnemiaHematologicCommonLow red blood cell count or hemoglobin
- Thrombosis (paradoxical)VascularRare
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection‑site reactionsLocalCommon
- BleedingHematologicCommonAbnormal bleeding or hemorrhage
- Hypersensitivity (urticaria, anaphylaxis)ImmuneRare
Drug Interactions
- Antiplatelet agents (aspirin, clopidogrel)Moderate
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)Moderate
- DextranModerate
- Heparin / Low-molecular-weight heparinsHigh
- WarfarinHigh
- NSAIDs / Antiplatelet agents (e.g., aspirin, clopidogrel)Moderate
- Heparin (unfractionated or low‑molecular‑weight)High
- Thrombolytics (e.g., alteplase)High
Population Constraints
- Pregnancy (Category C)ReproductiveRelative
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Pediatric patients (<18 y)AgeAbsolute
- Renal impairment (moderate to severe)RenalAbsolute
- Elderly patientsAgeRelative
- Severe renal impairment (CrCl <30 mL/min)Organ ImpairmentRelative
- Patients with prior hirudin exposureImmunologicRelative
Regulatory Status
- European UnionApprovedApproved: Prophylaxis of DVT after orthopedic surgeryEMA‑approved; marketed under Iprivask.
- United StatesApprovedApproved: Prophylaxis of deep‑vein thrombosis after total knee replacementFDA‑approved, prescription‑only.
- United KingdomApprovedApproved: Prophylaxis of deep vein thrombosis following hip replacement surgeryPreviously available under Revasc brand; current commercial availability subject to change post-Brexit
FDA‑approved (2003) as Iprivask for DVT prophylaxis after total knee replacement; also approved in the EU for the same indication.
Evidence & Sources
- Journal ArticleModerateThiele T, Althaus K, Greinacher A2010-01-01T00:00:00.000000Z
- Journal ArticleModerateKaplan KL2003-01-01T00:00:00.000000Z
- Journal ArticleModerateLee CJ, Ansell JE2011-01-01T00:00:00.000000Z
Frequently Asked Questions
When is desirudin typically used instead of heparin?
Desirudin is recommended for anticoagulation when heparin causes heparin‑induced thrombocytopenia or when heparin’s indirect mechanism is undesirable, such as in certain venous thromboembolism or acute coronary syndrome scenarios.
How does desirudin differ from other direct thrombin inhibitors?
Like other DTIs, desirudin directly blocks thrombin, but it is a recombinant hirudin analog given subcutaneously, whereas agents such as bivalirudin are synthetic peptides and argatroban is administered intravenously.
What are the main safety concerns with desirudin?
The chief risk is bleeding, including potentially serious hemorrhage. Monitoring for bleeding signs and managing injection‑site reactions are important, especially in patients with renal dysfunction.
Can desirudin be taken orally?
No. Desirudin is formulated for subcutaneous injection only; oral direct thrombin inhibitors like dabigatran are separate agents.
Is desirudin approved for long‑term anticoagulation?
The abstracts note its approval for therapeutic anticoagulation, but they do not specify duration of use; clinical decisions about long‑term therapy depend on individual patient assessment.
What is Desirudin?
Desirudin is a recombinant hirudin analog that directly inhibits thrombin. It is approved for prescription use as a subcutaneous anticoagulant, particularly when heparin is unsuitable, such as in heparin‑induced thrombocytopenia (HIT) or other thromboembolic conditions.
What is Desirudin used for?
Desirudin is educationally associated with: Acute coronary syndrome anticoagulation, Treatment of acute DVT/PE, Prevention of pulmonary embolism, DVT prophylaxis after orthopedic surgery, Heparin-induced thrombocytopenia (HIT) anticoagulation, DVT prophylaxis after hip replacement. Educational only — not medical advice.
How is Desirudin administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Desirudin?
Reported adverse effects include: Hypersensitivity / allergic reactions, Injection site reactions, Thrombocytopenia, Bleeding (major and minor), Anemia, Thrombosis (paradoxical), Nausea, Injection‑site reactions, Bleeding, Hypersensitivity (urticaria, anaphylaxis). This list is not exhaustive — consult a qualified clinician.
Who should avoid Desirudin?
Recorded contraindications: Known hypersensitivity to desirudin or any excipient, Spinal/epidural anesthesia with concurrent anticoagulant use, Active major bleeding, Severe hepatic impairment (Child‑Pugh C), Hypersensitivity to hirudins or desirudin, Severe renal impairment (CrCl <31 mL/min), Irreversible coagulation disorders, Active bleeding or hemorrhagic diathesis. Consult a qualified clinician before use.